Stock EPRX EUPRAXIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Eupraxia Pharmaceuticals Inc.

Equities

EPRX

CA29842P1053

Market Closed - Toronto S.E.
Other stock markets
 01:30:00 01/06/2024 am IST 		5-day change 1st Jan Change
3.65 CAD -4.20% Intraday chart for Eupraxia Pharmaceuticals Inc. -6.41% -32.03%
23/05 Eupraxia Pharmaceuticals Expanding RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis MT
23/05 Eupraxia Pharmaceuticals Inc. Brief: Announcing Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eupraxia Pharmaceuticals Expanding RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. Brief: Announcing Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Sector Update: Health Care Stocks Lower Premarket Wednesday
Sector Update: Health Care
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
Eupraxia Pharmaceuticals Announces Data from the Phase 1b/2a RESOLVE Clinical Trial
Eupraxia Pharmaceuticals Reports Positive Data From Eosinophilic Esophagitis Treatment Study -- Shares Rise After Hours
Update On Eupraxia Pharmaceuticals: Now Up 40% In US After Hours, Was Up As Much As 70%
Eupraxia Pharmaceuticals Up 70% In US After Hours As Announces New "Positive" Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. Brief: Announcing New "Positive" Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. Announces New Positive Data from Resolve Phase 1B/2A Trial of Ep-104Gi for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. Brief: Says To Present Initial Results from Ongoing Phase 1b Study of EP-104GI for Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Eupraxia Pharmaceuticals Forms Gastrointestinal Clinical Advisory Board
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
Eupraxia Pharmaceuticals : Name and Address of Company - Form 6-K
Top Premarket Decliners
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EPRX Stock
  4. News Eupraxia Pharmaceuticals Inc.
  5. Other languages